Membranous and Cytoplasmic Expression of PD-L1 in Ovarian Cancer Cells - PubMed (original) (raw)
doi: 10.1159/000484109. Epub 2017 Oct 20.
Affiliations
- PMID: 29055949
- DOI: 10.1159/000484109
Free article
Membranous and Cytoplasmic Expression of PD-L1 in Ovarian Cancer Cells
Qiu-Xia Qu et al. Cell Physiol Biochem. 2017.
Free article
Abstract
Background: Expression of programmed death-ligand 1 (PD-L1) on tumor cells represents a powerful immune evasion pathway, but the role of intracellular or cytoplasmic PD-L1 has not been investigated in ovarian cancer cells.
Methods: Flow cytometry (FCM), Real-time PCR (qPCR), immunohistochemistry (IHC) and western blot were used to determine the expression of PD-L1 in ovarian cancer cells. The cytokines detected in the tumor or tumor associated macrophage (TAM) were used to treat cancer cells. PD-L1 blockade and silencing were used to elucidate the functional significance of cancer-related PD-L1 expression.
Results: Based on the results presented, PD-L1 was found variably expressed in the cytoplasm and the cell surface of both HO8910 and SKOV3 cells. TAM or IFN-γ, TNF-α, IL-10 and IL-6 released from TAM stimulated the expression of PD-L1 at the surface of the cancer cells. The IHC results were consistent with the data in vitro showing infiltration of TAM correlated with membranous PD-L1. The increases of PD-L1 at the surface were not due to a shift in the proportion of surface versus intracellular protein, but the contribution of extracellular signal-regulated kinase (ERK)1/2 and phosphoinositide 3-kinase (PI3K) pathway activation. As a consequence, inducible membranous PD-L1 expression on SKOV3 inhibited CD8+ T cell function, and cytoplasmic PD-L1 promoted cancer cell growth. Additionally, in mouse models, both PD-L1 and PD-1 mAb resulted in tumor growth inhibition and demonstrated a potential to decrease the number of PD-1+CD8+T cells.
Conclusion: We conclude that TAM induced PD-L1 on the cancer cells represents an immune evasion mechanism. The observations confirm the therapeutic potential of PD-L1/PD-1 mAb to reactivate anti-tumor immunity in ovarian cancer.
Keywords: Ovarian cancer; PD-L1; Tumor-associated macrophage.
© 2017 The Author(s). Published by S. Karger AG, Basel.
Similar articles
- The increase of circulating PD-L1-expressing CD68(+) macrophage in ovarian cancer.
Qu QX, Huang Q, Shen Y, Zhu YB, Zhang XG. Qu QX, et al. Tumour Biol. 2016 Apr;37(4):5031-7. doi: 10.1007/s13277-015-4066-y. Epub 2015 Nov 6. Tumour Biol. 2016. PMID: 26541760 - PD-L1 induced by IFN-γ from tumor-associated macrophages via the JAK/STAT3 and PI3K/AKT signaling pathways promoted progression of lung cancer.
Zhang X, Zeng Y, Qu Q, Zhu J, Liu Z, Ning W, Zeng H, Zhang N, Du W, Chen C, Huang JA. Zhang X, et al. Int J Clin Oncol. 2017 Dec;22(6):1026-1033. doi: 10.1007/s10147-017-1161-7. Epub 2017 Jul 26. Int J Clin Oncol. 2017. PMID: 28748356 - IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer.
Abiko K, Matsumura N, Hamanishi J, Horikawa N, Murakami R, Yamaguchi K, Yoshioka Y, Baba T, Konishi I, Mandai M. Abiko K, et al. Br J Cancer. 2015 Apr 28;112(9):1501-9. doi: 10.1038/bjc.2015.101. Epub 2015 Mar 31. Br J Cancer. 2015. PMID: 25867264 Free PMC article. - [Effect of cisplatin alone or combined with monoclonal anti-programmed death ligand-1 antibody on lung adenocarcinoma cell line SPCA-1 and T lymphocytes].
Pan X, Xing Y, Shi M, Zhou T, Qian B, Chen Y. Pan X, et al. Zhonghua Jie He He Hu Xi Za Zhi. 2014 Jun;37(6):416-20. Zhonghua Jie He He Hu Xi Za Zhi. 2014. PMID: 25200040 Chinese. - Immunomodulatory aspects in the progression and treatment of oral malignancy.
Kondoh N, Mizuno-Kamiya M, Umemura N, Takayama E, Kawaki H, Mitsudo K, Muramatsu Y, Sumitomo S. Kondoh N, et al. Jpn Dent Sci Rev. 2019 Nov;55(1):113-120. doi: 10.1016/j.jdsr.2019.09.001. Epub 2019 Oct 7. Jpn Dent Sci Rev. 2019. PMID: 31660091 Free PMC article. Review.
Cited by
- Bispecific T-Cell Engaging Antibodies Against MUC16 Demonstrate Efficacy Against Ovarian Cancer in Monotherapy and in Combination With PD-1 and VEGF Inhibition.
Yeku OO, Rao TD, Laster I, Kononenko A, Purdon TJ, Wang P, Cui Z, Liu H, Brentjens RJ, Spriggs D. Yeku OO, et al. Front Immunol. 2021 Apr 14;12:663379. doi: 10.3389/fimmu.2021.663379. eCollection 2021. Front Immunol. 2021. PMID: 33936101 Free PMC article. - miR-502-5p affects gastric cancer progression by targeting PD-L1.
You W, Liu X, Yu Y, Chen C, Xiong Y, Liu Y, Sun Y, Tan C, Zhang H, Wang Y, Li R. You W, et al. Cancer Cell Int. 2020 Aug 15;20:395. doi: 10.1186/s12935-020-01479-2. eCollection 2020. Cancer Cell Int. 2020. PMID: 32821248 Free PMC article. - iPSC-derived NK cells maintain high cytotoxicity and enhance in vivo tumor control in concert with T cells and anti-PD-1 therapy.
Cichocki F, Bjordahl R, Gaidarova S, Mahmood S, Abujarour R, Wang H, Tuininga K, Felices M, Davis ZB, Bendzick L, Clarke R, Stokely L, Rogers P, Ge M, Robinson M, Rezner B, Robbins DL, Lee TT, Kaufman DS, Blazar BR, Valamehr B, Miller JS. Cichocki F, et al. Sci Transl Med. 2020 Nov 4;12(568):eaaz5618. doi: 10.1126/scitranslmed.aaz5618. Sci Transl Med. 2020. PMID: 33148626 Free PMC article. - Therapeutic effect of dual CAR-T targeting PDL1 and MUC16 antigens on ovarian cancer cells in mice.
Li T, Wang J. Li T, et al. BMC Cancer. 2020 Jul 20;20(1):678. doi: 10.1186/s12885-020-07180-x. BMC Cancer. 2020. PMID: 32689954 Free PMC article. - Interleukin‑8 released by cancer‑associated fibroblasts attenuates the autophagy and promotes the migration of ovarian cancer cells.
Thongchot S, Jamjuntra P, Therasakvichya S, Warnnissorn M, Ferraresi A, Thuwajit P, Isidoro C, Thuwajit C. Thongchot S, et al. Int J Oncol. 2021 May;58(5):14. doi: 10.3892/ijo.2021.5194. Epub 2021 Mar 2. Int J Oncol. 2021. PMID: 33649784 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous